Category 3 abuse-deterrent study of the abuse-deterrent, extended-release morphine product Egalet 001.

Trial Profile

Category 3 abuse-deterrent study of the abuse-deterrent, extended-release morphine product Egalet 001.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Morphine (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Sponsors Egalet
  • Most Recent Events

    • 22 Sep 2016 Results published in an Egalet media release.
    • 22 Sep 2016 Results from this and intranasal abuse potential trial (see CTP 700258174) published in Pain Medicine, according to an Egalet Corporation media release.
    • 25 Aug 2016 According to an Egalet media release, the data of from trial would be presented PAINWeek 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top